D.E. Shaw & Co
VYGR icon

D.E. Shaw & Co’s Voyager Therapeutics VYGR Stock Holding History

D.E. Shaw & Co’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$381K Buy
+98,716
New +$389K ﹤0.01% 3979
2024
Q4 		– Sell
-118,828
Closed -$695K – 4931
2024
Q3 		$695K Sell
118,828
-86,773
-42% -$631K ﹤0.01% 3510
2024
Q2 		$1.63M Sell
205,601
-28,388
-12% -$238K ﹤0.01% 2841
2024
Q1 		$2.18M Sell
233,989
-172,055
-42% -$1.45M ﹤0.01% 2571
2023
Q4 		$3.43M Sell
406,044
-220,079
-35% -$1.6M ﹤0.01% 2237
2023
Q3 		$4.85M Sell
626,123
-321,850
-34% -$2.94M 0.01% 1831
2023
Q2 		$10.9M Buy
947,973
+319,501
+51% +$3.31M 0.01% 1274
2023
Q1 		$4.85M Sell
628,472
-60,228
-9% -$479K 0.01% 1956
2022
Q4 		$4.2M Sell
688,700
-16,076
-2% -$91.3K ﹤0.01% 2256
2022
Q3 		$4.17M Sell
704,776
-22,366
-3% -$143K 0.01% 2293
2022
Q2 		$4.3M Buy
727,142
+90,921
+14% +$614K 0.01% 2317
2022
Q1 		$4.85M Buy
636,221
+342,198
+116% +$1.53M ﹤0.01% 2348
2021
Q4 		$797K Buy
+294,023
New +$1M ﹤0.01% 4102
2020
Q3 		– Sell
-19,927
Closed -$251K – 4195
2020
Q2 		$251K Sell
19,927
-16,776
-46% -$195K ﹤0.01% 3697
2020
Q1 		$336K Sell
36,703
-153,303
-81% -$1.76M ﹤0.01% 3412
2019
Q4 		$2.65M Buy
190,006
+14,620
+8% +$213K ﹤0.01% 2248
2019
Q3 		$3.02M Sell
175,386
-88,076
-33% -$1.85M ﹤0.01% 2052
2019
Q2 		$7.17M Buy
263,462
+22,857
+9% +$523K 0.01% 1331
2019
Q1 		$4.61M Buy
240,605
+201,274
+512% +$2.62M 0.01% 1594
2018
Q4 		$370K Buy
+39,331
New +$505K ﹤0.01% 3256
2017
Q4 		– Sell
-10,621
Closed -$219K – 3759
2017
Q3 		$219K Buy
+10,621
New +$120K ﹤0.01% 3278

Other funds holding VYGR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co's VYGR Position: Q1 2026 in Review

D.E. Shaw & Co opened a new position in Voyager Therapeutics (VYGR) in Q1 2026: 98,716 shares worth $381K. The stake represents ﹤0.01% of the portfolio and ranks #3979 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in VYGR as recently as Q3 2024.

D.E. Shaw & Co first reported a position in VYGR in Q3 2017 and has held it in 21 quarters since. The position peaked at $10.9M in Q2 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • D.E. Shaw & Co held 98,716 shares of Voyager Therapeutics worth $381K as of Q1 2026.
  • Voyager Therapeutics was a new D.E. Shaw & Co position in Q1 2026.
  • Voyager Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #3979 holding.
  • D.E. Shaw & Co first reported a position in Voyager Therapeutics in Q3 2017 and has held it in 21 quarters since.
  • D.E. Shaw & Co's Voyager Therapeutics position peaked at $10.9M in Q2 2023.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.